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BACKGROUND: Ischemic colitis and serious complications of constipation have been reported in association with the
use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed
conventional therapies. This systematic review calculated the incidence of these adverse events in
alosetron-using patients in clinical trials and post-marketing surveillance.
METHODS: A panel of experts in epidemiology and functional bowel disorders reviewed clinical trial report forms
and FDA MedWatch forms of each reported case of ischemic colitis or serious complications of
constipation. Experts were blinded about whether patients used alosetron or placebo. Using
pre-specified criteria, experts rated the likelihood of an accurate diagnosis and an association
between medication use and adverse events. Cases that were not consistent with the reported
diagnosis or not possibly associated with medication use were eliminated from calculation of
incidence rates of adverse events.
RESULTS: Pooled data from clinical trials indicate an increased rate of ischemic colitis among alosetron-using
patients compared to placebo-using patients (0.15% vs 0.0%, respectively, p = 0.03), but there was
no significant difference in the rate of serious complications of constipation. All (19/19)
alosetron-using patients with ischemic colitis had reversible colitis without long-term sequelae.
Based on post-marketing surveillance data, the post-adjudication rate of ischemic colitis is 1.1 per
1,000 patient-years of alosetron use and the rate of serious complications of constipation is 0.66 per
1,000 patient-years of alosetron use.
CONCLUSION: The incidence of ischemic colitis and serious complications of constipation is very low and is rarely
associated with long-term sequelae or serious morbidity.
(Am J Gastroenterol 2006;101:1069–1079)
INTRODUCTION
Alosetron is a potent selective antagonist of serotonin 5-
HT3 receptors (1, 2), and it is effective in the treatment of
diarrhea-predominant IBS in women based on multiple ran-
domized controlled trials (RCT) (3–9). These RCTs demon-
strate that alosetron improves global IBS symptoms and indi-
vidual symptoms of abdominal discomfort, stool frequency,
stool consistency, and urgency. The drug exerts its benefi-
cial effects on IBS symptoms through various actions: (a)
increases in colonic compliance (2); (b) motor inhibitory ef-
fects in the gastrointestinal tract, resulting in the slowing of
small bowel and colonic transit (1); (c) decreases in chloride
and water secretion (10); and (d) its central inhibitory effect
on “limbic” brain regions, concerned with visceral perception
and autonomic circuits, which correlated with IBS symptom
improvement (11).
Reports of adverse events, including ischemic colitis and
serious complications of constipation, have been reported in
association with alosetron use and have created concerns re-
garding the safety of alosetron. During pre-marketing stud-
ies, four cases of possible ischemic colitis were reported in
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alosetron-using patients. After alosetron was introduced in
the Spring 2000, 80 cases of ischemic colitis and 100 cases of
serious complications of constipation were reported and mar-
keting of alosetron was voluntarily suspended in November
2000. Due to requests from IBS sufferers and patient ad-
vocacy groups, the U.S. Food and Drug Administration and
GlaxoSmithKline agreed to re-introduce alosetron in Novem-
ber 2002 with a more restrictive indication for the treatment
of women with severe diarrhea-predominant IBS who had
failed to respond to conventional therapy. After reintroduc-
tion in November 2002, use of alosetron was applied through
a comprehensive risk management plan.
Disorders of intestinal ischemia include acute mesenteric
ischemia (AMI), chronic mesenteric ischemia (CMI) which
may be called “intestinal angina,” and colonic ischemia which
is commonly called “ischemic colitis” (12, 13). Colonic is-
chemia or “ischemic colitis” is the most common type of
intestinal ischemia. Although it may result in chronic coli-
tis, colonic stricture, gangrene, or even fulminant universal
colitis (12, 13), this disorder is usually mild and transient
with most patients requiring no specific medical intervention
or hospitalization (12, 13). In fact, most cases are subclini-
cal and most ischemic colitis patients probably do not come
to medical attention because their symptoms are mild and
resolve spontaneously (13). Nevertheless, many physicians
may inappropriately equate the term “ischemic colitis” with
acute mesenteric ischemia or chronic mesenteric ischemia,
which are frequently associated with serious morbidity and
even mortality (12, 13).
Serious complications of constipation may include fecal
impaction, intestinal/ileus obstruction, toxic megacolon, and
intestinal perforation. According to FDA guidelines, the na-
ture of serious complications of constipation should meet
the regulatory definition of “serious adverse events,” which
indicate that the constipation results in: (a) death; (b) a life-
threatening experience; (c) inpatient hospitalization or pro-
longation of existing hospitalization; (d) a persistent or sig-
nificant disability/incapacity; (e) a congenital anomaly/birth
defect; or, (f ) based on appropriate medical judgment, con-
stipation jeopardizes the patient and medical/surgical inter-
vention is required to prevent one of the outcomes listed in
this definition (14). Since alosetron exerts motor inhibitory
effects in the gastrointestinal tract and results in decreased
propulsion (15), the pharmacologic mechanism for constipa-
tion reported in alosetron-using patients is clear.
It is important to quantify the rates and characteristics of
serious adverse events associated with alosetron use in order
to educate patients and physicians and to guide IBS man-
agement. Therefore, the objective of this study was to sys-
tematically review clinical trials and post-marketing surveil-
lance data in order to calculate the rate of ischemic colitis
and serious complications of constipation in alosetron-using
patients and to define the sequelae associated with these ad-
verse events. This review evaluated reported adverse events
in on-going as well as previously completed clinical trials
and adverse events reported during post-marketing surveil-
lance in 2000 as well as since reintroduction in November
2002. In order to complete this process, experts in epidemi-
ology and functional gastrointestinal disorders (L.C., W.D.C.,
L.H., K.O., C.S.) completed a blinded screening procedure
and a blinded adjudication procedure using pre-specified cri-
teria and calculated estimated rates of ischemic colitis and
serious complications of constipation among alosetron-using
patients.
METHODS
Literature Search and Study Selection Criteria
A search of the Medline database from 1995 to 2004 was per-
formed using multiple combinations of the following medical
subject heading (MeSH) terms: “colonic diseases, func-
tional”; “irritable bowel syndrome”; “clinical trial”; “alos-
etron.” Review of the EMBASE database from 1995 to 2004
was performed by combining the term “alosetron” with “clin-
ical trial.” To access published literature not yet included in
the Medline database, Current Contents/Science Edition was
searched between 2002 and 2004 combining the key words
“alosetron” with “clinical trial.” A recursive search of the bib-
liographies of selected studies was also performed to identify
pertinent papers. Study selection criteria were (a) population-
alosetron-treated patients; (b) English language; (c) human;
and (d) report on frequency of adverse events. Data on study
population, dose of medication, duration of treatment, and
type of adverse events were extracted by a single researcher.
The U.S. Food and Drug Administration web site and reports
(14, 16–18) were also reviewed for relevant data.
Information about all of the adverse events is in the pub-
lic domain, and GlaxoSmithKline facilitated obtaining these
data. In order to calculate incidence rates from clinical trials
and post-marketing surveillance data, GlaxoSmithKline pro-
vided data about the number of patients in on-going clinical
trials and for alosetron prescriptions. GlaxoSmithKline also
provided copies of post-marketing FDA MedWatch forms
and clinical trial adverse event form reporting events of is-
chemic colitis and serious complications of constipation re-
ported through February 2004. GlaxoSmithKline personnel
also provided data about the total number of patients treated
with alosetron and placebo in GSK-sponsored studies. In or-
der to maintain an “arm’s length” relationship and impartial
assessment of adverse event data, no further communication
between GlaxoSmithKline personnel and study personnel oc-
curred during evaluation of data.
Screening and Adjudication Procedure
In order to identify all potential cases of ischemic colitis and
serious complications of constipation, the following proce-
dures were followed. For post-marketing surveillance cases of
serious complications of constipation, any MedWatch form
that was coded with the word “constipation” and “serious
adverse event” was reviewed. For ischemic colitis, any Med-
Watch form that was coded with the word “colitis” was
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Table 1. Screening Criteria to Identify Potential Cases of Ischemic Colitis
Probable: Medical history is consistent with ischemic colitis (e.g., abdominal discomfort, hematochezia, and diarrhea) and is supported by
the results of colonoscopy (e.g., segmental colitis in the watershed area of the splenic flexure) or other imaging test and/or histological
evaluation of a relevant tissue biopsy (e.g., pathologist’s report states that mucosal biopsies of colon are consistent with ischemia) and
there is no evidence for any more likely diagnosis.
∗Undetermined/pending: Positive medical history. Results of colonoscopy, other imaging modalities or tissue histology are pending.
†Insufficient data: Medical history may be positive or inconclusive or inadequate. (e.g., FDA MedWatch form from patient states “I was
diagnosed with ischemic colitis” and no other supporting medical information is available.) No data about any imaging modalities or
tissue histology were available or were obtained.
†Probably not: The results of imaging tests or histology are negative or support a different more probable diagnosis.
If majority of adjudication panel voted for “probably not,” then the case was eliminated from further review because ischemic colitis probably did not occur. If majority of
adjudication panel voted “insufficient data,” then the case was eliminated from further review because inadequate data was available to determine if ischemic colitis actually
occurred. Classification of a case as “insufficient data” does not imply the absence of an adverse event.
#∗No cases were classified as “undetermined/pending.”
†A case was only classified as “insufficient data” if no radiologic or endoscopic studies were performed since the FDA’s current adjudication criteria for ischemic colitis requires
at least one radiologic or endoscopic study in order to make the diagnosis of ischemic colitis. A case was only classified as “probably not” if hospital records, imaging tests, and
histologic results clearly indicated a different diagnosis (e.g., C. dificile colitis proven by colonoscopy and stool studies).
reviewed, regardless of severity of the adverse event (i.e., if
the case was not coded as “serious adverse event,” even then
it was still reviewed). A similar process was followed with
adverse event report forms from all on-going and completed
clinical trials. Cases of rectal bleeding were not revisited.
Diagnostic Criteria: Assessing the Likelihood of an
Accurate Adverse Event Diagnosis
Criteria for determining if a patient truly had ischemic colitis
or a serious complication of constipation (Tables 1 and 2)
were established prior to the screening procedure. Based on
current FDA adjudication practices, four screening categories
were established: probable, undetermined/pending, insuffi-
cient data, and probably not. For clinical trial cases, each
adverse event case was presented in a blinded fashion (i.e.,
experts did not know if alosetron or placebo was administered
in each case because all references to study medication were
deleted). Following presentation of each adverse event case,
experts asked questions and discussed the case, then each
expert voted by secret ballot about the appropriate screening
category for the adverse event case. If the majority of con-
sultants voted “probably not” or “insufficient data,” then the
case was excluded.
Table 2. Screening Criteria to Identify Potential Cases of Serious Complications of Constipation
Probable: Medical history is consistent with serious complication of constipation (e.g., patient complained of constipation and met
regulatory definition of serious adverse event∗) and medical history is supported by hospital/medical records. Results of colonoscopy (or
other imaging test) do not identify a more likely diagnosis for patient’s symptoms.
†Undetermined/pending: Positive medical history. Results of hospital/medical records, colonoscopy, or other imaging modalities are
pending.
‡Insufficient data: Medical history may be positive or inconclusive. No data about hospital/medical records or imaging modalities were
available or were obtained.
‡Probably not: The results of hospital/medical records or imaging tests are negative or support a different more probable diagnosis.
∗Serious Complication of Constipation refers to adverse events of constipation that meet the U.S. Food and Drug Administration definition of a serious adverse event. Serious
adverse event is defined as: “death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant
disability/incapacity, a congenital anomaly/birth defect.” Serious adverse events also include: “important medical events that may not result in death, be life-threatening, or require
hospitalization. . . [but] based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
listed in the definition.”
†No cases were classified as “undetermined/pending.”
‡A case was only classified as “insufficient data” if no medical records were available and the FDA medwatch report came from a non-healthcare professional. A case was only
classified as “probably not” if medical records clearly indicated that the case did not rise to the level of serious complication of constipation (e.g., patient did not even require
outpatient treatment in an emergency department or another acute care facility).
Adjudication Criteria: Assessing the Association between
Adverse Events and Medication Use
Criteria for assessing the association between medication use
and adverse events (Table 3) were established prior to the
adjudication procedure. Five categories of association were
established: definitely related; probably related; possibly re-
lated, probably not related; definitely not related. Guidelines
to categorize the association between medication use and ad-
verse events were established prior to the adjudication pro-
cedure (Table 4). Again, for clinical trial cases, each adverse
event case was presented in a blinded fashion (i.e., experts
did not know if alosetron or placebo was administered in
each case because all references to study medication were
deleted). Experts in functional (GI) disorders included mem-
bers of the ROME III committee on Functional GI Disorders
(L.C., W.D.C., K.O.), experts in infectious colitis (C.S.) and
functional GI disorders (L.H.). These experts have all pub-
lished multiple manuscripts and guidelines on the manage-
ment of functional GI disorders. Following the presentation
of each adverse event case, experts asked questions and dis-
cussed the case. Experts then completed a checklist about
criteria to assess the association between medication use and
adverse event and voted by secret ballot about the category of
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Table 3. Criteria for Assessing the Association Between Study Medication Use and Adverse Event (Ischemic Colitis or Serious Complication
of Constipation)
1. Were symptoms prompting adverse event report present before the patient started medication?
2. Did the diagnosis of the adverse event occur before the patient started medication?
3. Was the patient on medication long enough for the adverse event to be related to the medication?
4. Was the patient off medication too long for the adverse event to be realistically related to the medication?
5. Was there a realistic competing cause for the adverse event?
6. Was there objective evidence (e.g., pathology, radiographs) to support the diagnosis of the adverse event?
7. Did the symptoms of the adverse event resolve after the therapy was stopped (positive dechallenge)?
8. Did the symptoms of the adverse event return after therapy was reinstituted (positive rechallenge)?
These criteria are GUIDES to determine if the adverse event was definitely related, probably related, possibly related, probably not related, or definitely not related. Ultimately,
experts utilized their judgment and clinical expertise to assess the data from a case and decide if medication use was associated with an adverse event.
association between study medication use and adverse event.
If all consultants voted “probably not related” or “definitely
not related” for a specific case, then that case was excluded
(i.e., no possible association between study medication use
and adverse event). For clinical trial cases, the blinding code
was not broken until after consultants completed voting.
For post-marketing surveillance cases, blinding was not
possible. Since all post-marketing surveillance patients obvi-
ously used alosetron (i.e., no placebo-using patients among
post-marketing surveillance cases), experts might be biased
and exclude obvious cases of ischemic colitis or serious
complications of constipation. Also, if experts were biased,
then they might state no association between medication use
and adverse events for every post-marketing surveillance
case. Therefore, additional “dummy” cases were added to the
screening and adjudication procedure for the post-marketing
surveillance cases. These “dummy” cases were intentionally
constructed to present a classic history of ischemic colitis or
serious complication of constipation and to suggest an asso-
ciation between medication use and adverse event. If experts
excluded these “dummy” cases, then this would suggest that
consultants were biased and inappropriately excluded obvi-
ous adverse event cases. During the adjudication process, all
“dummy cases” were considered serious adverse events and
rated as “probably associated” with alosetron use, indicating
that consultants did not exclude obvious cases of serious ad-
verse events associated with alosetron use during evaluation
of post-marketing surveillance cases.
Data Analysis
Rates (cases per total number of patients treated) of ischemic
colitis and serious complications of constipation among clin-
ical trial patients were calculated for all reported cases (i.e.,
prescreening), all reported cases with an accurate diagno-
sis of ischemic colitis or serious complication of constipa-
tion (i.e., postscreening), and all reported cases of ischemic
colitis or serious complications of constipation with pos-
sible association to alosetron use (i.e., postadjudication).
Event rates (cases per 1,000 patient-years of use) from post-
marketing surveillance cases of ischemic colitis and seri-
ous complications of constipation were also calculated for
pre-screening, post-screening and post-adjudication cases.
Table 4. Category of Association Between Medication and Adverse
Event (Ischemic Colitis or Serious Complication of Constipaton)
Definitely related
Exposure and sequence is correct. Symptoms develop after
patient starts medication; adverse event diagnosed after
patient starts medication; patient on medication long enough
for adverse event to be related to medication use; adverse
event diagnosed during medication use or shortly after
discontinuation of medication.
Positive de-challenge: symptoms of adverse event resolve with
withdrawal of medication.
Positive rechallenge: symptoms of adverse event return with
reinstitution of medication.
No obvious competing cause that led to adverse event.
Objective evidence to support the diagnosis of an adverse event.
Probably related
Exposure and sequence is correct.
Positive de-challenge.
No rechallenge.
No obvious competing cause that led to adverse event.
Objective evidence to support the diagnosis of an adverse event.
Possibly related
Exposure and sequence is correct.
De-challenge ambiguous or negative.
No rechallenge.
No obvious competing cause that led to adverse event.
Objective evidence to support the diagnosis of an adverse event.
Probably not related
Exposure and sequence partly correct.
Competing cause(s) are more likely cause of adverse event.
Ambiguous or conflicting evidence to support the diagnosis of
an adverse event.
De-challenge ambiguous or negative.
No re-challenge.
Definitely not related
Exposure and sequence mostly incorrect: symptoms of adverse
event develop before patient starts medication; adverse event
diagnosed long after patient stops medication; adverse event
diagnosed before patient starts medication.
Competing cause(s) are more likely cause of adverse event.
Ambiguous or conflicting evidence to support the diagnosis of
adverse event.
De-challenge ambiguous or negative.
No re-challenge.
An adverse event case does not need to fulfill all criteria in a specific category in
order to be classified in that category. The criteria in each category are GUIDES to
determine if an adverse event was definitely related, probably related, possibly related,
probably not related, or definitely not related to medication use. Experts utilized their
judgment and clinical expertise to assess the data from a case and decide if use of
medication use was associated with an adverse event.
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A priori, sub-group analysis was planned to determine: (a)
incidence rates of adverse events in clinical trials and post-
marketing surveillance prior to reintroduction in November
2002 and after reintroduction in November 2002; (b) in-
cidence rates for specific types of intestinal ischemia, in-
cluding colonic ischemia, chronic mesenteric ischemia and
acute mesenteric ischemia; and (c) rates of hospitalization,
surgery and death associated with ischemic colitis, and seri-
ous complications of constipation. Separate analyses of post-
marketing adverse event rates prior to and after reintroduction
in November 2002 may be important because utilization of
alosetron in clinical trials and clinical practice since reintro-
duction has been restricted to women with severe IBS-D who
have failed to respond to conventional therapy. This popula-
tion may represent a different group of patients compared to
patients who used alosetron following its initial approval in
2000 when it was approved for women with IBS-D.
Incidence rates of adverse events from completed/
terminated and on-going clinical trials are pooled to calculate
an overall incidence for alosetron-using patients and placebo-
using patients. Fisher’s exact test (2 sided) was used to deter-
mine if there was a statistically significant difference in the
incidence of ischemic colitis or serious complications of con-
stipation between alosetron-using patients and placebo-using
patients in clinical trials. For incidence of adverse events dur-
ing post-marketing surveillance, overall incidence rates and
incidence rates per patient-years of alosetron use were calcu-
lated assuming that each alosetron prescription represented
1 month of alosetron use.
Demographic data on all cases of ischemic colitis and se-
rious complications of constipation were recorded, includ-
ing mean age, length of treatment prior to adverse event,
gender, and associated nonsteroidal antiinflammatory drugs
(NSAIDs) or estrogen/oral contraceptive use. Descriptive sta-
tistical data are presented in tabular form. No logistic regres-
sion analysis was attempted to determine if any of these fac-
tors was associated with adverse events because data on these
potential risk factors for the alosetron-using population that
did not experience adverse events were not available.
RESULTS
Characteristics of Selected Studies and Post-Marketing
Surveillance Data
Twenty-six clinical trials (3–9, 17–22) satisfied the study se-
lection criteria (Fig. 1). Twenty-four of these trials were com-
pleted or terminated at the time of withdrawal of alosetron in
November 2000, and two trials are currently on-going. Since
an unbalanced randomization schedule was utilized in mul-
tiple studies and since some studies were non-randomized
safety studies, more study patients received alosetron (n =
11,874) than placebo (n = 3,500) (17). After reintroduction of
alosetron in June 2002, additional patients were randomized
to standard doses of alosetron (n = 441) or placebo (n = 178)
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Figure 1. Results of literature search.
als, exact numbers of patients in placebo and alosetron groups
were unavailable. We estimated the number of patients using
alosetron and placebo based on the number of patients en-
rolled by February 6, 2004 and based on the randomization
schedule.)
From February 2000 through November 2000, 316,882
patients received 586,000 prescriptions, producing 48,829
patient-years of alosetron use during the initial post-
marketing surveillance period (17). After reintroduction of
alosetron in November 2002 through January 2003, 12,032
patients received 39,163 prescriptions, producing another
3,263 patient-years of use (18). These data are higher than
previous estimates since they account for non-retail sales to
mail-order pharmacies, hospitals, and clinics, and retail sales
to chain pharmacies, independent pharmacies, and pharma-
cies in supermarkets.
Incidence of Ischemic Colitis in Clinical Trials
Tables 5 and 6 lists the pre-screening, post-screening and
post-adjudication incidence of ischemic colitis from clini-
cal trials before and after June 2002 (date of reintroduction
of alosetron). Overall, there were 20 possible cases of is-
chemic colitis in alosetron-using patients in clinical trials,
and one case was eliminated during the screening process
because it did not meet the criteria for diagnosis of ischemic
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Table 5. Incidence of Ischemic Colitis During Clinical Trials Prior
to November 2000 (Prior to FDA Approval for Reintroduction of
Alosetron)
Alosetron Placebo
(n = 11,874) (n = 3500) p Value
All reported cases
(Prescreening)
18 (0.15%) 2 (0.06%) 0.41
All reported cases with
accurate Dx (Postscreening)
17 (0.14%) 0 (0.0%) 0.03
All reported cases with
accurate DX and possible
association with alosetron
use (Postadjudication)
17 (0.14%) 0 (0.0%) 0.03
Statistical comparison based on Fisher’s exact test (two-sided).
colitis. Of the remaining 19 cases, all were considered at
least possibly associated with alosetron use. The mean age
was 50 yr, 100% were women, and 53% used oral contra-
ceptives or hormone replacement therapy concurrently. Of
total, 42.1% suffered ischemic colitis within 1 wk of alos-
etron use, while an additional 21.0% suffered ischemic colitis
on days 8–30 of alosetron use (Table 7). Of the two possible
cases of ischemic colitis in placebo-using patients, both cases
were eliminated during the screening process because they
did not meet the criteria for the diagnosis of ischemic coli-
tis. A statistically significant increase in the post-adjudication
incidence of ischemic colitis for alosetron-using patients ver-
sus placebo-using patients was apparent after pooling of data
from all trials (0.15% vs 0.0%; p = 0.03). Based on 19 total
cases of ischemic colitis during 2,991 total patient-years of
alosetron use in clinical trials, the rate of ischemic colitis is
6.4 cases per 1,000 patient-years compared to 0.0 case per
1,000 patient-years of placebo use.
Among the 19 cases of ischemic colitis reported in
alosetron-using patients in clinical trials, all cases were re-
versible colitis without long-term sequelae (Fig. 8). There
were no cases of acute or chronic mesenteric ischemia. Nine
of the ischemic colitis patients were hospitalized, none had
abdominal surgery, and there were no deaths.
Table 6. Incidence of Ischemic Colitis During Clinical Trials After
June 2002 (After FDA Approval for Re-Introduction of Alosetron)
∗Alosetron ∗Placebo
(n = 441) (n = 178) p Value
All reported cases
(Prescreening)
2 (0.4%) 0 (0.0%) 1.00
All reported cases with
accurate IC
DX(Postscreening)
2 (0.4%) 0 (0.0%) 1.00
All reported cases with
accurate IC DX and possible
association with alosetron
use (Postadjudication)
2 (0.4%) 0 (0.0%) 1.00
Does not include patients in alosetron clinical trials that use prn doses of medication.
∗These data come from on-going, double-blind trials. Exact numbers of patients in
alosetron arm and placebo arm have not been unblinded. The number of patients in
the alosetron and placebo arm reflect estimates based on the total number of patients
enrolled in these trials and the randomization schedules used.
Table 7. Demographic Data for Alosetron-Using Patients Suffering






% on NSAIDs 16
% on estrogen or oral contraceptives 53
% on anti-diarrheal medication 11
% on narcotic medication 5
Time on medication until symptoms is 1–7 days 42.1%
Time on medication until symptoms is 8–30 days 21.0%
Time on medication until symptoms is 31–90 days 21.0%
Time on medication until symptoms is greater 15.8%
than 90 days
Incidence of Serious Complications of Bowel Dysfunction
in Clinical Trials
Tables 8 and 9 list the pre-screening, post-screening and post-
adjudication incidence of serious complications of constipa-
tion from clinical trials before November 2000 and after June
2002 (date of reintroduction of alosetron). Overall, there were
14 possible cases of serious complication of bowel dysfunc-
tion in alosetron-using patients in clinical trials, and three
cases were eliminated during the screening process because
they did not meet diagnostic criteria. Of the remaining 11
cases, one was eliminated because no association with study
medication could be demonstrated. The mean age was 50.4 yr,
100% were women, 10% used anti-diarrheal medication con-
currently and 10% used narcotics concurrently. No cases oc-
curred within the first 7 days of use, although 40% of cases
occurred on days 8–30 of alosetron use (Table 10). Of the two
possible cases of serious complications of bowel dysfunction
in placebo-using patients, both cases met diagnostic crite-
ria for serious complications of bowel dysfunction, but one
was eliminated because no association with study medication
could be demonstrated. There was no significant difference
in the rate of serious complications of bowel dysfunction
between placebo-using patients and alosetron-using patients
Table 8. Incidence of Serious Complications of Constipation During
Clinical Trials Prior to November 2000 (Prior to FDA Approval for
Reintroduction of Alosetron)
Alosetron Placebo
(n = 11,874) (n = 3,500) p Value
All reported cases
(Prescreening)
12 (0.10%) 2 (0.06%) 0.69
All reported cases with
accurate DX
(Postscreening)
10 (0.084%) 2 (0.06%) 1.00
All reported cases with
accurate DX and possible
association with alosetron
use (Postadjudication)
9 (0.076%) 1 (0.03%) 1.00
Statistical comparison based on Fisher’s exact test (two-sided).
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Table 9. Incidence of Serious Complications of Constipation During
Clinical Trials After June 2002 (After FDA Approval for Reintro-
duction of Alosetron)
Alosetron Placebo
(n = 441) (n = 178) p Value
All reported cases
(Prescreening)
2 (0.4%) 0 (0.0%) 1.00
All reported cases with
accurate DX (Postscreening)
1 (0.2%) 0 (0.0%) 1.00
All reported cases with
accurate DX and possible
association with alosetron
use (Postadjudication)
1 (0.2%) 0 (0.0%) 1.00
Does not include patients in alosetron clinical trials that use prn doses of medication.
in clinical trials. Based on 10 total cases of serious complica-
tions of constipation during 2,991 total patient-years of alos-
etron use in clinical trials, the rate of serious complications
of constipation is 3.3 cases per 1,000 patient-years compared
to 1.0 case per 1,000 patient-years of placebo use.
Among the 10 cases of serious complications of bowel
dysfunction in aloseton-using patients, all were hospitalized,
one underwent abdominal surgery and none died. One case
of serious complications of constipation was associated with
ischemic colitis occurring secondary to constipation.
Incidence of Ischemic Colitis in Post-Marketing
Surveillance
Table 11 lists the pre-screening and post-adjudication inci-
dence of ischemic colitis from post-marketing surveillance.
There was no significant difference in rates of ischemic col-
itis during initial use of alosetron (prior to November 2000)
compared to post-reintroduction (after November 2002). Of
89 possible cases of ischemic colitis, 35 cases were eliminated
during the screening process. The majority (>90%) of these
cases were eliminated because there was no documentation
of a medical evaluation, although a minority of cases were
eliminated because they did not meet diagnostic criteria due
to the absence of diagnostic testing (e.g., no endoscopic or
radiologic imaging of colon). Of the remaining 54 cases, one
case was eliminated because reviewers determined that there
Table 10. Demographic Data for Alosetron-Using Patients Suffering
Serious Complications of Constipation in Completed and On-Going





% on NSAIDs 20%
% on estrogen or oral contraceptives 40%
% on anti-diarrheal medication 10%
% on narcotic medication 10%
Time on medication until symptoms is 1–7 days 0%
Time on medication until symptoms is 8–30 days 40%
Time on medication until symptoms is 31–90 days 50%
Time on medication until symptoms is greater than 90 days 10%
was no possible association with alosetron use. The post-
adjudication rate of ischemic colitis in the post-marketing
surveillance population is estimated at 1.0 case per 1,000
patient-years. In these cases, the mean age was 53.5 yr, 98%
were women, and 42% used oral contraceptives or hormone
replacement therapy concurrently (Table 12). Ischemic colitis
occurred within 7 days of use in 28% of patients and during
days 8–30 in 21% of patients (Table 12). Among the 54 cases
of ischemic colitis reported in post-marketing surveillance,
52 were cases of reversible colitis with one case of colonic
stricture and one case of gangrene. Thirty-six of these pa-
tients were hospitalized with three undergoing surgery and
no deaths.
In post-marketing surveillance, there were also 12 reported
cases of acute or chronic mesenteric ischemia in the previous
marketing cycle, although four of these cases were elimi-
nated during screening because they did not meet diagnostic
criteria and another three were eliminated because reviewers
determined that there was no possible association with alos-
etron use. Of the remaining five patients, all were hospitalized
and underwent surgery and one died. According to previous
review by FDA officials, all five patients had complicated
medical histories with other risk factors for vascular disease
and the potential association with alosetron is unclear. All five
of these cases occurred prior to reintroduction of alosetron in
November 2002.
Incidence of Serious Complications of Constipation in
Post-Marketing Surveillance
Table 11 also lists the pre-screening and post-adjudication
incidence of serious complications of constipation from
post-marketing surveillance. Again, there was no significant
difference in rates of serious complications of constipation
during initial use of alosetron (prior to 2002) compared to
post-reintroduction (after 2002). Of 108 possible cases of se-
rious complication of bowel dysfunction, 74 were eliminated
during the screening process because they did not meet di-
agnostic criteria. The majority (>90%) of these cases were
eliminated because there was no documentation of medical
evaluation, although a minority of cases were eliminated be-
cause they did not meet diagnostic criteria for a serious com-
plication of constipation (e.g., patient with constipation who
did not require even outpatient treatment in an emergency
department or other acute care facility). Of the remaining
34 cases, three were eliminated because reviewers determined
that no association with alosetron could be demonstrated. Of
the remaining 31 cases, the mean age was 56.4, 97% were
women, 42% of patients used oral contraceptives or hor-
mone replacement therapy concurrently, and 26% of cases
occurred within 7 days of treatment and 32% occurred dur-
ing days 8–30 of treatment (Table 13). The post-adjudication
rate of serious complications of bowel dysfunction in
the post-marketing surveillance population is estimated at
0.6 cases per 1,000 patient-years (Table 11). Among the 31
cases of serious complications of constipation , 29 were hos-
pitalized, 10 had surgery, and two deaths were associated with
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Table 11. Incidence of Ischemic Colitis and Serious Complications of Constipation During Post-Marketing Surveillance (Reported in Rate
per 1,000 Patient-Years of Use)
Before June 2002 After June 2002 Total
(n = 48,829 pt-yrs) (n = 3263 pt-yrs) (n = 52,092 pt-yrs)
Ischemic colitis (all reported cases/prescreening) 1.7 per 1,000 pt-yrs 2.5 per 1,000 pt-yrs 1.7 per 1,000 pt-yrs
Ischemic colitis (all reported cases with accurate Dx and
possible association with alosetron use/postadjudication)
0.96 per 1,000 pt-yrs 1.53 per 1,000 pt-yrs 1.0 per 1,000 pt-yrs
Serious complication of constipation (all reported
cases/prescreening)
2.0 per 1,000 pt-yrs 2.5 per 1,000 pt-yrs 2.1 per 1,000 pt-yrs
Serious complications of constipation (all reported cases
with accurate Dx and possible association with alosetron
use/postadjudication)
0.59 per 1,000 pt-yrs 0.61 per 1,000 pt-yrs 0.60 per 1,000 pt-yrs
these adverse events. Three cases of serious complication of
constipation were associated with secondary ischemic colitis
(i.e., ischemic colitis occurred due to constipation causing
compression of colonic mucosa).
DISCUSSION
This study represents the first external, blinded, systematic
review of ischemic colitis and serious complications of con-
stipation in patients using alosetron. This review of clinical
trials and post-marketing surveillance data estimates the in-
cidence of ischemic colitis and serious complications of con-
stipation in alosetron-using patients and defines the seque-
lae associated with these adverse events. Pooled clinical trial
data demonstrate an increased risk of ischemic colitis among
alosetron-using patients (0.15% vs 0.0%, p = 0.03), but do
not demonstrate an increase in serious complications of con-
stipation. Notably, all clinical trial patients diagnosed with
ischemic colitis suffered a transient colitis without long-term
sequelae. Post-marketing surveillance data estimates that the
rate of ischemic colitis is 1.0 per 1,000 patient-years of alos-
etron use and the rate of serious complications of constipation
is 0.60 per 1,000 patient-years of alosetron use. With these
data, women with severe diarrhea-predominant IBS who are
considering using alosetron may be appropriately educated
about the risks associated with alosetron use.
Table 12. Demographic Data for Alosetron-Using Patients Suffering





% on NSAIDs 16
% on estrogen or oral contraceptives 42
% on anti-diarrheal medication 2
% on narcotics 2
Time on medication until symptoms is 1–7 days 28.4%
Time on medication until symptoms is 8–30 days 26.4%
Time on medication until symptoms is 31–90 days 11.3%
Time on medication until symptoms is greater 20.8%
than 90 days
Time on medication until symptoms unknown 13.2%
When educating prospective patients about the risk of
ischemic colitis associated with alosetron use, two issues
should be noted. First, intestinal ischemia associated with
alosetron use is virtually always colonic ischemia, which is
transient and rarely associated with no long-term sequelae or
the need for hospitalization. Acute mesenteric ischemia and
chronic mesenteric ischemia, which are associated with sig-
nificant morbidity and mortality, have not been reported in
alosetron-using patients in clinical trials nor during postmar-
keting since reintroduction. Second, alosetron-associated is-
chemic colitis is infrequently (<10%) associated with severe
constipation in clinical trials and in post-marketing surveil-
lance. Consequently, severe constipation does not appear to
be a requisite for the development of ischemic colitis.
Recent studies (23–26) indicate that IBS patients are more
likely to be diagnosed with ischemic colitis compared to
healthy controls (Table 14). The precise explanation for this
association is unclear, although some symptoms of ischemic
colitis and IBS (e.g., abdominal discomfort) are similar,
which may make it difficult to rule out a random association
of two conditions with similar clinical expression in some
patients. For example, it is conceivable that some ischemic
colitis patients are initially misdiagnosed as suffering from
IBS (27). However, even patients who carry the IBS diag-
nosis for greater than 1 yr have a five-fold increase in the
subsequent diagnosis of ischemic colitis compared to healthy
Table 13. Demographic Data for Aloestron-Using Patients Suffer-
ing Serious Complications of Constipation during Post-Marketing





% on NSAIDs 19%
% on estrogen or oral contraceptives 42%
% on anti-diarrheal medication 10%
% on narcotic medication 19%
Time on medication until symptoms is 1–7 days 25.8%
Time on medication until symptoms is 8–30 days 32.3%
Time on medication until symptoms is 31–90 days 12.9%
Time on medication until symptoms is greater 16.1%
than 90 days
Time on medication until symptoms unknown 12.9%
Ischemic Colitis and Serious Complications of Constipation 1077
Table 14. Incidence of Ischemic Colitis in IBS and Non-IBS Popu-
lations (per 1,000 Patient-Years)
Source Non-IBS IBS
Medi-Cal: 1995–2002 (25) 0.5 1.8
United Health Care: 1995–1999 (24) 0.01 0.4
CORI database: 2000–2003 0.2 0.9
controls (27), suggesting that misdiagnosis is not the sole ex-
planation for the association between ischemic colitis and
IBS. Second, IBS patients do undergo colonoscopy more
frequently than healthy controls (28), which may create an
ascertainment bias. For example, an IBS patient who is fol-
lowed by a gastroenterologist may be more likely to get an
urgent colonoscopy for abdominal discomfort with hema-
tochezia and be diagnosed with ischemic colitis compared to
a healthy individual with similar symptoms who would have
their colonoscopy delayed until after referral from a primary
care physician or might not even seek medical care if the
symptoms are transient and self-limited. Third, pathophysi-
ologic abnormalities in IBS patients may actually increase
the risk of ischemic colitis. Recent data demonstrate that
both ulcerative colitis and IBS are associated with molecu-
lar changes in serotonergic signaling mechanisms (29). Since
serotonin signaling could affect colonic mucosal circulation,
it is conceivable that this might account for the increased
incidence of ischemic colitis in IBS patients (30).
Though the etiology of ischemic colitis in alosetron-using
IBS patients is unclear, several explanations are possible.
First, 5-HT3 receptor antagonists may allow available sero-
tonin to interact with other serotonin receptor sub-types (5-
HT1 receptors) known to influence vascular perfusion in ani-
mals with damaged endothelium due to disease (30). Second,
5-HT released from enterochromaffin cells is thought to play
a role in the coordination of motor activity and mucosal blood
flow in the intestine by activating sensory myenteric and/or
submucosal neurons which in turn activate vasodilatory neu-
rons (31). Thus, it is conceivable that blockade of 5-HT3
receptors interferes with the protective mechanisms of mu-
cosal and submucosal vasodilatation. Third, the development
of severe constipation with associated colonic distention and
local vascular compression may infrequently contribute to
the development of ischemic colitis. It is notable that only
three cases of ischemic colitis in post-marketing surveillance
and one case from clinical trials were associated with se-
vere constipation. Finally, alosetron-associated ischemic col-
itis may not represent classic ischemic colitis but rather it
may reflect a different type of drug-associated colitis similar
to NSAID-associated colitis. Certainly, there were no consis-
tent pathologic findings in alosetron-using patients diagnosed
with ischemic colitis and endoscopic abnormalities were re-
ported to affect sections of the colon other than the classic
“watershed” areas of the splenic flexure and sigmoid colon.
Risk factors for colonic ischemia include increasing age,
female gender, cardiovascular disease, vascular surgery, pre-
disposition to thromboembolism, and co-morbid illnesses in-
cluding IBS and COPD (13, 23, 32). A logistic regression
analysis to search for risk factors associated with alosetron-
associated ischemic colitis is beyond the scope of the study
because it would require more complete demographic data
on alosetron-using patients who did not suffer from these
events. Nevertheless, our demographic data clearly indicate
that a substantial percentage (>25%) of ischemic colitis cases
and serious complications of constipation cases occur within
the first 7 days of use and the majority of these adverse events
occur within the first 30 days. Therefore, both patients and
physicians should be particularly vigilant about monitoring
for symptoms suggestive of ischemic colitis or severe con-
stipation during the first 30 days of treatment. This fact em-
phasizes the need for education of patients as required by
the alosetron risk management program: early recognition
and management of constipation and ischemic colitis should
reduce the frequency of sequelae from adverse events. In
fact, there have been no surgeries, mesenteric ischemia, or
deaths among alosetron-using patients since reintroduction
in November 2002.
The screening and adjudication process was designed
to minimize the possibility that true cases of alosetron-
associated adverse events would be excluded. The screening
criteria were very broad and minimal medical history was re-
quired to confirm the diagnosis of adverse events. During the
adjudication process, the primary reason for excluding possi-
ble cases of ischemic colitis or severe constipation was absent
or insufficient medical data (e.g., An FDA MedWatch form
that states “my sister used alosetron and she was diagnosed
with ischemic colitis. No other information available”). The
adjudication procedure attempted to minimize bias through
several mechanisms: (a) experts were blinded about whether
patients used alosetron or placebo for clinical trial cases; (b)
criteria to determine the association between study medica-
tion use and adverse events were objective and specified prior
to the screening procedure and adjudication procedure; (c) for
post-marketing surveillance cases, “dummy” patients were
added to ensure that the experts did not perform a biased ad-
judication (i.e., automatically stating no association between
study medication and adverse events); and (d) if even a single
expert stated a possible association between study medica-
tion use and adverse event, then that case was included in
the post-adjudication calculation of adverse event incidence
rates. With this adjudication procedure, only adverse event
cases that could not be associated with study medication were
excluded.
Our study has several limitations. First, adverse events as-
sociated with medication use may be under-reported, par-
ticularly during post-marketing surveillance. Therefore, data
from clinical trials are more likely to reflect the true inci-
dence rate of adverse events than data obtained during post-
marketing surveillance. Our data reinforce this hypothesis
since adverse events were reported more frequently in the
clinical trials than during post-marketing surveillance. How-
ever, we think that under-reporting for alosetron-associated
adverse events may have been minimized due to the extensive
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publicity in the lay media about alosetron-associated is-
chemic colitis. Second, during the adjudication of post-
marketing surveillance reports of serious adverse events, we
eliminated reports with insufficient data to make a diagnosis
of ischemic colitis or serious complications of constipation.
Nevertheless, some of these patients may have truly had a se-
rious adverse event. Therefore, we provided “pre-screening”
rates and “post-adjudication” rates for serious adverse events
in Table 13, which provides a high and low estimate of the rate
of serious adverse events during post-marketing surveillance.
Third, the definitions of ischemic colitis and serious compli-
cations of constipation and the screening criteria (Tables 1
and 2) are vague, but these definitions and screening criteria
were adapted from current FDA adjudication criteria. Future
studies may benefit from using more precise definitions and
screening criteria.
In conclusion, an increased incidence of ischemic coli-
tis among alosetron-using patients versus placebo-using pa-
tients was demonstrated in pooled analysis of clinical trial
data (0.15% vs 0.0%, p = 0.03). Post-marketing surveil-
lance data estimates that the rate of ischemic colitis is
1.0 per 1,000 patient-years of alosetron use, although this
figure may slightly underestimate the rate since all cases of
ischemic colitis reported during post-marketing use may not
have been reported. All clinical trial patients with ischemic
colitis suffered a transient colitis without long-term sequelae.
The frequency of serious complications of bowel dysfunction
is similar among alosetron-using patients and placebo-using
patients in clinical trials, and the post-marketing surveil-
lance rate of serious complications of constipation is only
0.60 per 1,000 patient-years of use. Although risk factors for
alosetron-associated adverse events have not yet been clearly
identified, the majority of adverse events occured within
30 days of initiating therapy. Therefore, patients and physi-
cians should be particularly attentive during this time period.
These data should facilitate education of health care providers
and patients who are considering alosetron for management
of severe IBS-D. Further studies to determine possible risk
factors for alosetron-associated ischemic colitis, to deter-
mine possible mechanisms of action for this insult, and to
explore the possibility that alosetron causes a previously un-
described form of drug-induced colitis are warranted. Data
from such studies should help clinicians better identify those
patients at significantly increased risk for suffering these ad-
verse events.
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STUDY HIGHLIGHTS
What Is Current Knowledge Alosteron is effective in a proportion of women with
diarrhea predominant irritable bowel syndrome (IBS). Alosteron is associated with rare serious adverse events
related to ischemic colitis and constipation (fecal im-
paction, ileus, toxic megacolon, perforation). The incidence of serious adverse events is unknown.
What Is New Here A systematic review of clinical trials suggests ischemic
colitis and serious complications of constipation oc-
curred at a rate of 6.4 and 3.3 per 1000 patient years
respectively in patients allocated to alosetron. Post-marketing surveillance gave lower estimates of
risk. There were no deaths and all cases of ischemic colitis
in clinical trials were reversible.
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